To investigate the determinants of KIF18A dependency in cancer, we used AM-1882, a highly specific small molecule KIF18A inhibitor (KIF18Ai) developed by Amgen Inc (Payton et al, 2023; Tamayo et al, 2022). The gene discussed is KIF18A; the disease is cancer.